Abstract:Therapeutic drug monitoring (TDM) of imatinib (IM) in cancer therapy offers the potential to improve treatment efficacy while minimizing toxicity. There was a significant correlation between unbound concentration and clinical response and toxicity, compared with total plasma concentrations, and the quantification of unbound IM and its metabolite, N-desmethyl imatinib (NDI) are of interest for TDM. However, traditional unbound drug separation methods have shortcomings, especially are susceptible to non-specific binding (NSB) of drugs to the polymer-constructed components of filter membranes, which are difficult to avoid at present. Hence it is necessary to developed a reliable separation method for the analysis of the unbound fraction of IM and NDI in TDM. We developed and validated an hollow fiber solid phase microextraction (HF-SPME) method coupled with high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) that to measure unbound IM and NDI concentration in human plasma. It used the NSB phenomenon and solve the NSB problem. The preparation procedure only involves a common vortex and ultrasonication without dilution of samples and modification of membrane. A total of 50 chronic myeloid leukemia (CML) patients were enrolled in our study. The relationship between the unbound and total concentrations for IM and NDI, as well as the concentration ratios of NDI to IM in 50 clinical plasma samples were investigated. The extraction recovery is high to 95.5-106 % with validation parameters for the methodological results were all excellent. There were both a poor linear relationship between the unbound and total concentrations for IM (r2=0.504) and NDI (r2=0.201) in 50 clinical plasma samples. The unbound concentration ratios of NDI to IM varied widely in CML patients. The determination of unbound IM and NDI concentration is meaningful and necessary. The developed HF-SPME method is simple, accurate and precise that could be used to measure unbound IM and NDI concentration in clinical TDM.

Bioequivalence of Two Kinds of Imatinib Preparations in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on Bioequivalence of Indinavir Capsule in Healthy Volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Determination of Gliquidone in Human Plasma by LC-MS/MS and Bioequivalence Study of Its Two Tablets

Determination of Telmisartan in Human Plasma by LC-MS/MS and Bioequivalence Study of It

Bioequivalence of Two Domestic Praperations of Metformin Hydrochloride Entericcoated Capsules in Chinese Healthy Volunteers

Bioequivalence of glycyrrhizin capsules by HPLC-MS

Consideration on the bioequivalence study of imatinib mesylate oral products

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

Phase 0 clinical trial of single -dose imatinib mesylate in health Chinese male volunteers

Pharmacokinetics and bioequivalance of domestic compound glibenclamide and metformin in chinese healthy volunteers

Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.

Simultaneous Determination of Paracetamol and Amantadine in Human Plasma and Bioequivalence of Its Preparations in Healthy Volunteers by LC-MS

A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions

Bioequivalence of trimetazidine dihydrochloride tablets in Chinese healthy subjects

Determination by HPLC-MS-MS Method and Bioequivalence of Clemastine in Health Volunteers

Evaluation of Bioequivalence of Mirtazapine Tablets

Pharmacokinetics and Bioequivalence of Telmisartan Tablets and Capsules

Simultaneous Determination of Gefitinib and Its Major Metabolites in Mouse Plasma by HPLC-MS/MS and Its Application to a Pharmacokinetics Study.

Development of an hollow fiber solid phase microextraction method for the analysis of unbound fraction of imatinib and N-desmethyl imatinib in human plasma